Chimeric Polypeptide Vaccine for Single-Dose Immunocastration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for immunocastration using GnRH-I vaccines face challenges such as antigenic dominance, high costs, and the need for repeated vaccinations due to the use of carrier proteins, which suppress the immune response and require multiple injections for long-term effectiveness.
Innovation Solution
A chimeric polypeptide or glycopeptide is developed by fusing the GnRH-I amino acid sequence with a non-pathogen-derived theoretical sequence, enhancing immunogenicity and allowing for single-dose long-term effects without the use of carrier proteins, and incorporating glycosylation for improved antigenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If carrier proteins are used to conjugate GnRH-I, then immunogenicity is improved, but antigenic dominance and suppression of immune response occur
Solution Approach 1:
The patent removes the carrier protein component from the vaccine formulation, using only synthetic GnRH-I peptide sequences. This extraction eliminates the harmful antigenic dominance and immune suppression effects caused by carrier proteins while maintaining immunogenicity through optimized peptide design and adjuvant combinations.
Solution Approach 2:
The patent uses multiple tandem repetitions of the GnRH-I peptide sequence to create a synthetic antigen that mimics the immunogenicity of carrier-protein conjugates without actually using carrier proteins. The repeated peptide sequences provide sufficient immunogenicity through themselves when combined with appropriate adjuvants.
2Reliability
If carrier proteins are used in GnRH-I vaccines, then initial immune response is improved, but repeated vaccinations are required for long-term effectiveness
Solution Approach 1:
The patent changes the formulation parameters by eliminating carrier proteins and optimizing the peptide sequence repetitions and adjuvant combinations. This parameter change enables a single vaccination to produce long-lasting immunocastration effects, eliminating the need for repeated vaccinations while maintaining effective immune response.
3Reliability
If chemical synthesis of haptens is used to link GnRH to carrier proteins, then immunogenicity is improved, but synthesis cost increases
Solution Approach 1:
The patent eliminates the need for complex chemical synthesis of hapten-carrier conjugates by using only synthetic GnRH-I peptide sequences that can be produced through simpler processes. This extraction of the carrier protein component significantly reduces synthesis costs while maintaining immunogenicity.
Solution Approach 2:
The patent uses multiple copies of the simple GnRH-I peptide sequence arranged in tandem repetitions, which are easier and less expensive to synthesize than unique hapten-carrier conjugates. The repeated peptide structure simplifies the synthesis process and reduces overall manufacturing cost.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution achieves significant immune response and long-term immunocastration with a single vaccine dose, effectively blocking steroidogenesis, oogenesis, and spermatogenesis, as demonstrated by increased immunoglobulin levels and reduced testosterone concentrations in animal models.
Implementation Method 1
incorporating glycosylation for improved antigenicity
Implementation Method 2
to immunoneutralize the gonadotrophin-releasing hormone (GnRH-I) producing a block in steroidogenesis, oogenesis and spermatogenesis
Data Source
AI summary
Fusion protein for immunocastration (Sequences la and Ib) that comprises the primary amino acid sequence of the gonadotrophin-liberating protein fused to a theoretical sequence:Sequence la NH2-QHWSYGLRPGGPPFSGGGGPPFSA-COOH (SEQ ID NO: 1)Sequence Ib NH2-GPPFSGGGGPPFSAQHWSYGLRPG-COOH (SEQ ID NO: 2);DNA sequences coding for said fusion protein; vaccine comprising said fusion protein; use of the fusion protein for mammal immunocastration; process for producing the vaccine; process for preparing the fusion protein that comprises fusing the amino acid sequence of the gonadotrophin-liberating hormone (GnRH-I) to a theoretical glycosilable sequence having immunogenic activity that does not include pathogen or “carrier” protein sequences in its structure.